Skip to main content
. 2015 Aug 10;33(26):2877–2884. doi: 10.1200/JCO.2015.60.9818

Fig 1.

Fig 1.

(A) Cumulative incidence of recurrence (CIR) of patients with stage I lung adenocarcinoma. (B) CIR for patients with stage I lung adenocarcinoma for each architectural grade. (C) Hazard function of recurrence for architectural grade tumors. (D) Hazard function of recurrence for solid predominant tumors.